



Article

Structural Basis for Agonistic Activity and Selectivity toward Melatonin Receptors *hMT1* and *hMT2*

Mattia Cantarini, Dario Rusciano, Rosario Amato, Alessio Canovai, Maurizio Cammalleri, Massimo Dal Monte, Cristina Minnelli, Emiliano Laudadio, Giovanna Mobbili, Giorgia Giorgini et al.

Topic Collection

Feature Papers in Molecular Pharmacology

Edited by
Prof. Dr. Peter Illes





Article

Structural Basis for Agonistic Activity and Selectivity toward Melatonin Receptors *hMT1* and *hMT2*

Mattia Cantarini ¹, Dario Rusciano ², Rosario Amato ³, Alessio Canovai ³, Maurizio Cammalleri ³, Massimo Dal Monte ³, Cristina Minnelli ¹, Emiliano Laudadio ⁴, Giovanna Mobbili ¹, Giorgia Giorgini ¹ and Roberta Galeazzi ^{1,*}

¹ Department DISVA, Università Politecnica delle Marche, Via Breccie Bianche, 60131 Ancona, Italy

² Fidia Pharma Group, Research Center, 95100 Catania, Italy

³ Department of Biology, University of Pisa, 56127 Pisa, Italy

⁴ Department SIMAU, Università Politecnica delle Marche, Via Breccie Bianche, 60131 Ancona, Italy

* Correspondence: r.galeazzi@staff.univpm.it

Abstract: Glaucoma, a major ocular neuropathy originating from a progressive degeneration of retinal ganglion cells, is often associated with increased intraocular pressure (IOP). Daily IOP fluctuations are physiologically influenced by the antioxidant and signaling activities of melatonin. This endogenous modulator has limited employment in treating altered IOP disorders due to its low stability and bioavailability. The search for low-toxic compounds as potential melatonin agonists with higher stability and bioavailability than melatonin itself could start only from knowing the molecular basis of melatonergic activity. Thus, using a computational approach, we studied the melatonin binding toward its natural macromolecular targets, namely melatonin receptors 1 (MT1) and 2 (MT2), both involved in IOP signaling regulation. Besides, agomelatine, a melatonin-derivative agonist and, at the same time, an atypical antidepressant, was also included in the study due to its powerful IOP-lowering effects. For both ligands, we evaluated both stability and ligand positioning inside the orthosteric site of MTs, mapping the main molecular interactions responsible for receptor activation. Affinity values in terms of free binding energy (ΔG_{bind}) were calculated for the selected poses of the chosen compounds after stabilization through a dynamic molecular docking protocol. The results were compared with experimental *in vivo* effects, showing a higher potency and more durable effect for agomelatine with respect to melatonin, which could be ascribed both to its higher affinity for *hMT2* and to its additional activity as an antagonist for the serotonin receptor 5-HT_{2c}, in agreement with the *in silico* results.

Keywords: melatonin receptors; glaucoma; melatonergic agonists; molecular docking; molecular dynamics; drug design



Citation: Cantarini, M.; Rusciano, D.; Amato, R.; Canovai, A.; Cammalleri, M.; Monte, M.D.; Minnelli, C.; Laudadio, E.; Mobbili, G.; Giorgini, G.; et al. Structural Basis for Agonistic Activity and Selectivity toward Melatonin Receptors *hMT1* and *hMT2*. *Int. J. Mol. Sci.* **2023**, *24*, 2863. <https://doi.org/10.3390/ijms24032863>

Academic Editor: Daniela Impellizzeri

Received: 13 January 2023

Revised: 30 January 2023

Accepted: 31 January 2023

Published: 2 February 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Glaucoma is a chronic, long-term disease that can be classified within the ocular neuropathies characterized by progressive degeneration of retinal ganglion cells [1]. Nowadays, glaucoma pharmacological and surgical treatments are focused on IOP control in an attempt to delay its progression. One of the main factors contributing to glaucoma onset and progression involves circadian system deregulation. Several studies have shown the alteration of the melatonergic system in glaucomatous cases [2–4]. Melatonin is a circadian neurotransmitter produced in different districts of the body, including the eye, where it is involved in the control of daily physiological IOP fluctuations [5,6]. Excluding its intrinsic antioxidant activity, melatonin participates actively in the signaling pathway to decrease IOP in *Homo sapiens* by activating the human melatonin receptors 1 (*hMT1*) and 2 (*hMT2*) [7]. Thus, the clinical use of melatonin could help restore a physiological situation in glaucomatous eyes thanks to its antioxidant and signaling activities. However,

this endogenous ligand has low chemical stability and bioavailability [8]. Therefore, we set out to find melatonin agonists with high melatonergic activity, possibly associated with high stability and low toxicity. We addressed, by an *in silico* approach, the binding modes of melatonin and one of its derivatives, agomelatine (Figure 1), within the orthosteric sites of *hMT1* and *hMT2* to evaluate the necessary molecular basis for agonist binding. Despite being a melatonin-derivative, agomelatine shows better chemical stability than its parent compound, and its crystallographic binding pose within the orthosteric site of *hMT1* [9] can help retrieve much useful information to explore both human melatonergic target structures and the active binding poses for ligands to be tested [10]. Moreover, agomelatine is also used in antidepressant therapy for its atypical action that involves both the melatonergic and the serotonergic pathways, through antagonist binding to the serotonin receptor 5HT_{2C} [11]. To validate the computational results, we used normotensive rats and rats with increased IOP to measure the effects of melatonin/agomelatine eye drops, comparing them with those drugs commonly used to reduce IOP in glaucoma patients. The hypotensive effect of melatonin and agomelatine on normotensive rats was evaluated as well.




Figure 1. 2D structure of melatonin and its agonist agomelatine.

2. Results and Discussion

2.1. Structural Features of *hMT1* and *hMT2*

According to the current classification A–F [12,13] and ‘GRAFS’ [14] systems of amino acid sequence similarity for G-protein coupled receptors (GPCR), melatonin receptors (MTs) belong to the class A or ‘rhodopsin-like family’, which in turn represent the largest GPCR superfamily [12,15]. More precisely, *hMTs* present a topology characterized by a counter-clockwise bundle of seven-pass transmembranes (TMs) and the association with guanine nucleotide-binding proteins (G proteins), which are two peculiarities of all the members belonging to the wide GPCRs superfamily [16].

Considering the protein structures in light of the inactive and active states of the β_2 -adrenergic receptor (prototype of GPCRs class A) [17,18], the available crystallographic data about MTs represent molecular complexes of the inactive receptor-binding melatonergic agonists [10,19]. Crystallized MTs binding melatonin-like activity ligands show an inactive conformation because they are induced by the presence of chimeric parts to thermo-stabilize the polypeptide chain during the crystallization process. Generally, an agonist binds better to the active form of the receptor than to the inactive one. Moreover, the literature indicates that the binding modes of the ligand and the residues of the orthosteric site of the GPCR are conserved during the transition from the inactive to the active form and vice versa [20]. Therefore, the available crystallized MTs could be used to search for new potential melatonergic agonists [20,21]. The built-up structures of *hMT1* and *hMT2* are in an inactive conformation since they conserve spatial atomic coordinates of the starting crystallographic structures of 6ME3 [10] and 6ME6 [19].

The built-up structures of *hMTs* present a hepta-helical counter-clockwise bundle with an extracellular N-ter and intracellular C-ter domain. TMs are linked by three extracellular loops (ECLs) and three intracellular loops (ICLs) (Figure 2). The *hMTs* present a further short amphipathic helix (helix-VIII) with a parallel orientation to the intracellular membrane side [10,19].




Figure 2. Cont.




Figure 2. Snake plots reached by GPCRdb of the *hMTs* membrane topology, namely (A) *hMT1* and (B) *hMT2*. Each TM has its own X.50 residues (red), references for Ballesteros–Weinstein numeration, and amino acids of the membrane (light green), repositioning the proteins with OPM sever. Also present are ICL (pink), ECL (yellow), and VIII-helix (dark green). The ligand (melatonin) is reported in green sticks. (C) The alignment shows the topology of the residues of the orthosteric sites of *hMTs*. Additionally, the snake graphs illustrate the residue distribution on the protein domains, associating the Ballesteros–Weinstein numeration to each residue of the clefts [21,22].

MTs participate in melatonergic signal transduction, activated by melatonin, its endogenous neurotransmitter, after binding in its orthosteric site. Crystallographic data on the spatial disposition of melatonin within MT pockets are not available yet. However, in PDB [23], different crystallized structures are available, matching the macromolecular complexes of MT1 and MT2 with known melatonergic agonists [10,19]. The superimposition of crystallized structures on the *hMTs* allows for more accurate identification of the ligand binding domain on human receptors. Both the *hMT1* and *hMT2* orthosteric sites include residues belonging to TMs 2,3,4,5,6,7, and ECL2 (Figure 3).

From a structural point of view, we found that *hMTs* orthosteric sites follow the same class A GPCRs superfamily topology, thus identifying *hMTs* clefts in an extracellular position of the receptor [10,19,24,25]. The assembly of all TMs, except TM1, constitutes the pocket sidewalls, and ECL2 the roof. The main differences between *hMT1* and *hMT2* protein domains are in the proximity of the roof, TM6 and ECL3 near ECL2, and sidewalls, with a final extremity of TM4. In *hMT2*, moving away the TM6 and ECL3 amino acidic backbone brings decreasing hydrophobic interactions with ECL2, maybe generating a further access route for the ligand¹⁹. This path seems to be impracticable in *hMT1*. On the other hand, *hMT1* shows a route between the helices TM4–TM5 for the access of ligands bigger than *hMT2* since the roof of the pocket, ECL2, is bound more strongly to TM1, TM2, and TM7 [10] (Figure 4).

To point out other differences within *hMTs* binding sites, we further evaluated the whole-cavity volumes to identify changes in sub-pockets accommodating ligand functions or cleft access routes.




Figure 3. Residues at the orthosteric site of hMT1 (A) and hMT2 (B), binding agomelatine (with the same pose in 6ME5) and 2-phenylmelatonin (with the same pose in 6ME6). Each color indicates the receptor domain. TM: transmembrane domain, ECL: extracellular loop.

Through the CASTp server online [26], we calculated cavity volumes for both orthosteric sites of *hMTs*. Using the alpha-shape method [27], the CASTp server [28] draws bulbs to describe geometric and topological features for each cavity present in the protein structure. This server retrieved each potential cavity of *hMTs* structures, measuring volume and area [29–31]. In line with crystallographic data, the calculated size of the *hMT2* cleft overcomes the *hMT1* volume by about 54.0 \AA^3 since CASTp [26] calculated a cavity volume of 194.5 \AA^3 for *hMT1* and 248.5 \AA^3 for *hMT2*. The main topological cavity differences were on the roof access route and in the sub-pocket accommodating indole C-2 substituents (Figure 5A). Different geometry of the *hMT2* pocket in the roof provides a communication channel oriented outside, supporting a potential access route for the ligand as previously described. The sub-pocket accommodating substituent in the C-2 position of melatonin-derivatives indole developed itself toward an intracellular direction, enhancing the *hMT2* pocket. Fewer changes involved sub-pockets where we found alkylamide and aromatic moieties of melatonin derivatives (Figure 4) [10,19].




Figure 4. The *hMT1* (orange) and *hMT2* (light blue) structures. Melatonin is always in green. (A) depicts all potential ligand access routes for *hMTs* orthosteric sites. (B) represents a comparison between *hMTs*' top-side paths. (C) shows the overall superimposition of both *hMT1* and *hMT2*.

The *hMTs* orthosteric sites present a similar amino acid pattern close to 5 Å from molecular probes. Cleft constituent residues mainly involved in binding show conserved spatial positions in the site. Hence, we identified through UCSF Chimera [32] and PLIP server online [33] which residues and their respective intermolecular interactions are important for ligand binding.

All the molecular probes are melatonin analogs, sharing common pharmacophoric features. Each melatonin-like compound shares a similar molecular structure composed of a condensed aromatic scaffold bound to C-3 alkylamide and C-5 alkoxy or de-hydro furan functions. Additionally, in 2-melatonin derivatives, a further substituent on the C-2 position is also present. Following the previously described simplified structural scheme for each molecular probe, we considered molecular moieties to give an orthosteric site overview (Figure 5) (Figures S1 and S2, Table S1).

The aromatic condensed system of each probe fits in a lipophilic sub-pocket of the protein site. Thus, aromatic core results flanked from TMs 3, 4, 5, and above have ECL2 as a roof. Both *hMTs* clefts present a prevalent hydrophobic nature for the presence of aliphatic side chains belonging to residues with conserved positions on protein domains. Mutagenesis studies showed the importance of F179^{ECL2} in *hMT1* and F192^{ECL2} in *hMT2* in the binding because isoleucine or alanine substitutions produced a loss of ligand affinity [10]. We noted the participation of all F^{ECL2} in a parallel π stacking intermolecular interaction with aromatic function to improve the global packaging of ligands in the pocket.




Figure 5. (A) pharmacophoric representation of melatonin analogs; (B) Spatial representation of disposition of pharmacophoric features in the 3D orthosteric site.

Even if the sub-pocket has lipophilic nature, it presents a conserved residue of N^{4.60} on TM4 of *hMTs*. The side chain of that residue act as a hydrogen bond donor towards lone pairs on the oxygen of ligand alkoxy or de-hydro furan functions. Despite its conservation in *hMTs*, the substitutions with alanine produce only *hMT1* inactivation, while *hMT2* retains its activity [10].

hMTs accommodate the ligand alkylamide function in a region of the orthosteric site defined by TMs 5 and 6 on sidewalls and ECL2 on the roof. Orientation of the alkylamide function assumes a ‘tail down’ or ‘tail up’ conformation towards Q181^{ECL2} of *hMT1* or Q194^{ECL2} of *hMT2*, respectively. The better conformation in the *hMT2* sub-cleft favors hydrogen bond formation between the ligand and glutamine side chain [10]. Some of the crystallized melatonin analogs present a further function on the C-2 position of the aromatic core, localized in a sub-pocket defined by TMs 2, 3, 5, and 6. Below the plane of the C-2 function, helix 6 presents a conserved CWXP motif, characteristic of GPCRs class A. In *hMTs*, we can see an amino acidic sequence CWAP which in turn has different residues employed in the binding and activation mechanism of the receptors [34–42]. Mutagenesis studies on residue P^{6.50}, respectively P253^{6.50} in *hMT1* and P266^{6.50} in *hMT2*, substituted with alanine show an unfavorable sub-pocket geometry that causes a complete loss of 2-iodomelatonin binding [42]. Thus, P^{6.50} results are important for the maintenance of the sub-cleft packaging. The CWXP motif presents a further conserved W^{6.48} that is involved in activating helices movements. The coupling between the W^{6.48} ‘rotamer toggle switch’ and D^{2.50} ‘allosteric switch’ is at the base of the ‘micro-switch’ mechanism of the receptor. The activation of this mechanism triggers the contraction of the TM3–TM5–TM6 interface, and the roto-translation of TM6 triggers the subsequent activation of the TM3 to TM7 movement. All these protein changes bring the recruitment of G-protein on the intracellular side of the receptor [43].

2.2. Exploration of Agonists' Binding Poses within MTs Orthosteric Sites

Taking advantage of the crystallographic data on the binding positions of melatonin analogs (agomelatine in 6ME5 [10] and 2-phenylmelatonin in 6ME6 [19]), we docked melatonin and its derivatives in the *h*MTs pockets. The similarities and differences in the binding modes between the two compounds and their affinity in terms of binding free energy (ΔG_{bind}) were deeply analyzed.

Agomelatine in 6ME5 [10] constituted an excellent starting and reference point in analyzing the molecular docking results of this melatonin-like compound within the orthosteric site of *h*MT1.

It was very difficult to set up the docking parameters to reproduce the crystallized pose of agomelatine in *h*MT1 as each docked cluster showed an ensemble with a small number of conformations and a ΔG_{bind} range close to 1 Kcal/mol. This peculiar behavior must be ascribed to the high conformational flexibility of agomelatine together with the width (volume) of the *h*MT1 orthosteric site. The accurate cluster selection was achieved by crossing the docking results with the agomelatine conformational population and energy achieved at the Density Functional Theory (DFT) level using B3LYP hybrid functional and 6-311G* basis set (G09 software) [44]. As a result, we found out that the cluster corresponding to the crystallized pose corresponds to the lowest energy minimum for agomelatine (2.8 kcal/mol lower than that of the conformation present in the most populated cluster), and thus this pose proceeded with MD simulation.

The same protocol was applied to choose the best docked ligand positions for agomelatine within the *h*MT2 pocket (Figure 6).

Agomelatine shows a more favorable ΔG_{bind} than melatonin with both *h*MT1 and *h*MT2, thus suggesting a higher stability for the corresponding complex concerning the natural ligand (Table 1). Furthermore, the scientific literature supports the *in silico* findings since the ability of agomelatine to bind MTs is slightly better than the melatonin one [45,46]. In addition, agomelatine shows a slightly higher affinity for *h*MT2 than *h*MT1, and this data is also supported by experimental evidence, even if agomelatine is not considered a selective agonist of *h*MT2 [9,47].

Table 1. Free Gibbs binding energies (ΔG_{bind}) associated with the docked poses are reported in Figure 6.

Receptor	Compound	Cluster Conformation	ΔG_{bind} (Kcal/mol)
<i>h</i> MT1	Melatonin	1 of 1	−6.42
	Agomelatine	2 of 7	−6.81
<i>h</i> MT2	Melatonin	1 of 1	−7.12
	Agomelatine	1 of 1	−7.52

2.3. Complexes Conformational Stability: Molecular Dynamics Simulations

As previously reported, applying a semi-flexible molecular docking protocol neglects the degrees of freedom of the biological molecular target, which only molecular dynamics could finalize, considering the whole system is flexible. Thus, starting from the selected docked conformations, we proceeded through MD stabilization to evaluate how the ligands' binding modes in the *h*MTs orthosteric site can evolve over time. Analyzing the MD trajectories, Root Mean Square Deviation (RMSD), as a measure of the positional deviation of the atoms of a structure and its reference [48], was calculated. In addition, the RMSD evaluates whether the molecular dynamics trajectories have reached an equilibrium state and the quality of the process (Figure S4). In Figure 7, the protein RMSD as a function of simulation time is represented. Each of the simulated systems reaches the equilibrium state within the first 50 ns. The protein structure of *h*MT1 binding agomelatine changes more during the simulation time and requires more time to reach a final steady state.




Figure 6. Docking poses of melatonin and agomelatine in hMT1 and hMT2 orthosteric sites. As a reference, the crystallographic conformation of agomelatine in 6ME5] for hMT1 (A) and melatonin in 6ME9] for hMT2 (B) are reported in red. The tested docked ligands are highlighted in green (melatonin on the left side, agomelatine on the right in both A,B sections).




Figure 7. RMSD plot of hMTs protein backbone in binding complex with melatonin or agomelatine, in the function of time.

The ligands' RMSD was also calculated along the MD trajectory and is reported separately (Figure S5). In MT2, the RMSD vs. time plot of both agomelatine and melatonin shows a very similar trend. In MT1, agomelatine's RMSD plot deviates prior to reaching

the equilibrium state due to a rearrangement of the ligand's conformation inside the cleft. This does not happen inside *hMT2*, in which the conformation of agomelatine changes less, suggesting a stronger binding affinity. The binding modes of melatonin in *hMT1* and *hMT2* remain similar to the starting poses. In Figure 8, the time evolution of H-bonding intermolecular interactions among ligands and receptors is reported along the MD trajectory.




Figure 8. H-bonding interaction evolution along the 100 ns MD trajectory.

Most hydrogen bonds are lost during the MD simulation trajectory. Except for the melatonin-*hMT2* complex, residues Q181^{ECL2} for *hMT1* and Q194^{ECL2} retain their hydrogen bonding (H-bonding) with the oxygen atom of the carbonyl group in the alkyl amide function of the ligands. The amide moiety of agomelatine acts as an H bond donor for the backbone carbonyl for N268^{6.52} in *hMT2*. The ligands' methoxy group is an H bond donor for the amide group of N175^{4.60/61}, the side chain in *hMT2*, but not for the corresponding residue N162^{4.60/61} in *hMT1*, which remains close to the methoxy function. Moreover, only in *hMT1* are the carbonyl oxygen atom of the T178^{ECL2} side chain and the carboxyl group of G104^{3.49} are involved in H bonding with the hydrogen atom attached to the melatonin indole nitrogen.

As previously anticipated, the aromatic scaffold is mainly stabilized by lipophilic interactions. According to MD simulations, F179^{ECL2} in *hMT1* and F192^{ECL2} in *hMT2* continue to bind the ligand. In particular, F^{ECL2} generates a π - π stacking interaction with the aromatic ring of melatonin in *hMT1* and agomelatine in *hMT2*. In addition, the interaction of M107^{3.32} in *hMT1* and M120^{3.32} in *hMT2* with the aromatic scaffold of agomelatine and melatonin is observed, respectively, while F^{ECL2} in the proximity of the ligand is involved in van der Waals hydrophobic interactions with the aromatic ring or methoxy group of the ligand. According to MD simulations, melatonin increases the number of π - or Van der Waals interactions close to the methoxy group. The *hMTs* preserve the topology of residues V^{5.42/43} (V191 in *hMT1*, V204 in *hMT2*) and X^{4.57} (V159 in *hMT1* and L172 in *hMT2*), residues used to generate alkyl interactions with the methoxy group. At the end of the MD simulation, agomelatine has a smaller number of π - or alkyl interactions stabilizing the naphthalene and methoxyl function with respect to the initial docked pose. All other residues listed in Figure 9 bind the ligand via weak van der Waals interactions. The number of these interactions is higher in the intermolecular complexes binding agomelatine than

in those binding melatonin. This could be due to the different aromatic framework of the ligand. At the end of the process, five topological positions of residues involved in van der Waals interactions with the ligand are conserved in all four simulated systems, namely F^{3.30} (F105 in *hMT1*, F118 in *hMT2*), G^{3.33} (G108 in *hMT1*, G121 in *hMT2*), V^{5.43/44} (V192 in *hMT1*, V205 in *hMT2*), L^{6.51} (L254 in *hMT1*, L267 in *hMT2*), and Y^{7.39/38} (Y281 in *hMT1*, Y294 in *hMT2*).





Figure 9. 3D representation of the final poses of melatonin and agomelatine in the *hMT1* and *hMT2* orthosteric site after 100 ns molecular dynamics simulations (docked poses starting for MD in green; final MD configuration in yellow) (for 2D mapping see Supplementary Materials Figure S3).

In Figure 10, MMPBSA energy for each ligand-receptor molecular complex studied focuses on the last 10 ns of MD simulations, in the time frames in which RMSD plot reveal that all complexes reached a steady state. MMPBSA energy change in function of simulation time shows that melatonin is more stable in the orthosteric site of *hMT1* than in *hMT2*. It is reversed for agomelatine in *hMT2*, where this derivative is more stable than the natural ligand. From the scientific literature, agomelatine has a better affinity for *hMTs* [9,49] than its natural ligand [9,50,51]. The time plot of MMPBSA energy for the *hMT2* ligand seems to show the same trend of energy between melatonin and its derivative. The MMPBSA plot of the melatonin-*hMT1* complex shows a lower free binding energy than agomelatine, suggesting that the natural ligand has the best affinity for the receptor.



Molecular complex	Average energy [KJ/mol]	Standard deviation [KJ/mol]
MT1-melatonin	-181	±15
MT1-agomelatine	-168	±13
MT2-melatonin	-141	±12
MT2-agomelatine	-175	±14

Figure 10. Melatonin and agomelatine affinity values towards *h*MTs in terms of free binding energy calculated using MMPBSA in 1 ns and molecular dynamics simulations.

In summary, the MMPBSA plot shows that melatonin has better stability in the *h*MT1 orthosteric site than in the *h*MT2 one, while the opposite is observed for agomelatine; overall, agomelatine shows a better affinity for *h*MTs [9,49] than the natural ligand, in line with the available experimental data [9,50,51].

2.4. IOP Effects In Vivo: Melatonin and Agomelatine Relative Efficacy

Melatonin 0.5% formulated in eye drops (see M&M) was given to rats, and its effects were compared with the hypotensive ability of commercially available drugs: timolol 0.5% and brimonidine 0.2%. These two agents are routinely used in the treatment of glaucoma because of their ability to lower the IOP, with brimonidine having selective α 2-adrenergic agonistic activity [52], while timolol is a β -blocker [53]. Figure 11A shows the hypotensive effect in normotensive animals. Timolol and brimonidine had similar efficacy, lasting about 2 h and decreasing IOP at peak (15–30 min) by 33% of the initial value. Melatonin effects lasted a little longer, up until 3 h, with a deeper IOP lowering effect (47% decrease over control value), also seen at 15–30 min from instillation. Figure 11B reports the results obtained in the hypertensive rat model, obtained by clogging the trabecular meshwork with 2% MCE. The relative ratios among the three eye drop products remained similar. Again, timolol and brimonidine showed almost superimposable curves, peaking at 15–30 min at a 25% decrease, with an efficacy lasting over 6 h. The melatonin effect peaked at 30 min at a 40% decrease, with the efficacy also lasting over 6 h. Figure 12 shows the comparison in the normotensive rat between the hypotensive effects of melatonin and agomelatine eye drops, both formulated at 0.2% (see M&M). A lower concentration was chosen in this case to show a dose-dependent effect in potency and duration. Both compounds peaked at 15 min at

around a 35% decrease. Likely due to the lower concentration, melatonin effects lasted only one hour, while agomelatine efficacy was protracted over 3 h.




Figure 11. Time-course of the hyponotizing effects of melatonin 0.5%, brimonidine 0.2%, and timolol 0.5% in normotensive (A) or hypertensive (B) rats. *** $p < 0.001$, ** $p < 0.01$, * $p < 0.05$ vs. control; ## $p < 0.01$ vs. timolol or brimonidine.

Thus, agomelatine was found to have a similar potency to melatonin but a longer-lasting efficacy in lowering the IOP. The same potency can be ascribed to a comparable affinity for the two *hMTs* receptors with respect to melatonin, as the computational data found; besides, the long-lasting effect could be instead attributed to the involvement of the serotonin receptor 5-HT_{2c}, which is not bound by the natural ligand melatonin. Further studies are currently underway to confirm this hypothesis.




Figure 12. Time-course of the hypotonizing effects of melatonin 0.2% vs. agomelatine 0.2% in normotensive rats. *** $p < 0.001$, ** $p < 0.01$, * $p < 0.05$ vs. control; ## $p < 0.01$, # $p < 0.05$ vs. melatonin.

2.5. Searching for Potential Melatonin Agonists: Test Case Studies

Using all the structural information obtained from the *in silico* results and considering that agomelatine inhibits the 5-HT_{2C} receptor besides its melatonergic effect, we performed a virtual screening of known antagonists/inverse agonists for this receptor towards MT1 and MT2 using Autodock Vina. Finally, we chose some promising compounds that bound efficiently into the orthosteric cavity. In Table 2, the binding affinities of three selected potential agonists are reported.

Table 2. Binding energies of best-scored compounds compared to melatonin and its agonist agomelatine one.

Receptor	Ligand	Molecular Docking ΔG_{bind}	Receptor	Ligand	Molecular Docking ΔG_{bind}
<i>h</i> MT1	Melatonin	−6.42 Kcal/mol	<i>h</i> MT2	Melatonin	−7.12 Kcal/mol
	Agomelatine	−6.81 Kcal/mol		Agomelatine	−7.52 Kcal/mol
	Ramelteon	−7.93 Kcal/mol		Ramelteon	−8.66 Kcal/mol
	Clozapine	−8.47 Kcal/mol		Clozapine	−8.33 Kcal/mol
	Flumazenil	−7.43 Kcal/mol		Flumazenil	−7.71 Kcal/mol

3. Material and Methods

3.1. D Protein Modeling

Human melatonin receptors (*h*MTs) crystallographic structures were obtained from the Brookhaven Protein Data Bank (www.rcsb.org/pdb) [23] [pdb codes 6ME3 for *h*MT1 and 6ME6 for *h*MT2, both in complex with a melatonin agonist, 2-phenylmelatonin]. The retrieved 3D structures were aligned with the FASTA sequences reported in UniProt [54] P48039 (*h*MT1) and P49286 (*h*MT2) to identify any aminoacidic differences or lacking residues.

In both structures, engineered chimeric proteins bonded to the receptors used for the crystallization process were present; therefore, they were firstly removed, then substituted with the receptor residues according to UniProt *h*MTs sequences [54] to obtain the full *h*MTs 3D structures, i.e., P23^{1.28}-V318^{C-ter} of the sequence P48039 for *h*MT1 and W38^{1.30}-N328^{VIII-helix} of the sequence P49286 for *h*MT2. Both structures present a disulfide bridge between C^{3.25/25}-C^{ECL2}, respectively C100^{3.25/25}-C177^{ECL2} in *h*MT1 and C113^{3.25/25}-C190^{ECL2} in *h*MT2. After adding hydrogen atoms using CHIMERA [32], each structure has been submitted to OPM-Orientations of Proteins in Membranes database [55] to get the *h*MTs spatial distribution in the biological membrane through comparison with the spatial

disposition of known proteins characterized by similar structure, classification topology, and cellular localization in relation to the analyzed structure [56]. The whole protein structure of each *h*MTs has been aligned and cross-compared to investigate the orthosteric site composition to better elucidate the aminoacidic interactions with the ligands.

Key residues involved in ligand recognition, molecular docking, and molecular dynamics have been highlighted through UCSF Chimera [32], PLIP server online [33], and Discovery Studio [57]. After a detailed evaluation of the pockets' aminoacidic composition, their volume was calculated with the CASTp server [26], which used the alpha shape method [27] to describe geometric and topological features for each cavity and their own volume and area [28–31]. Finally, the macromolecular receptors were minimized and stabilized in their biological environment prior to proceeding with the docking calculations.

3.2. *h*MTs Ligands Docking

Ligands were prepared using UCSF CHIMERA software³² (i.e., melatonin, the natural ligand of melatonin receptors (MTs), and agomelatine, a melatonin-mimetic compound exerting activity like the natural ligand) [9,58] (Figure 1).

An *in silico* dynamic docking protocol was set to compare the ligands' binding poses in the *h*MTs orthosteric sites. Dynamic docking combines molecular docking with atomistic molecular dynamics simulation to improve the exploration of the mechanism and free binding energy (ΔG_{bind}) behind ligand-protein interaction [59]. Initially, via semi-flexible molecular docking, the best binding modes between two molecular partners [60] were predicted in the *h*MTs orthosteric site. Autodock4.0 software [61] was used concerning *h*MTs with fixed atomic spatial coordinates and ligand flexibility to explore its conformational space, including all ligands' torsional degrees of freedom. The previous knowledge regarding the position of the *h*MTs orthosteric sites allowed the execution of a focused docking on these pockets, setting up the grid box size: for *h*MT1: $70 \times 68 \times 66 \text{ \AA}^3$ and *h*MT2: $76 \times 70 \times 58 \text{ \AA}^3$.

The genetic algorithm (GA) setting the runs to 100 and the Lamarckian genetic algorithm (LGA) for data analysis were used to identify the best scored binding poses [62]. The best poses were selected according to their lowest ΔG_{bind} values (high affinity). Since the crystallographic data about *h*MTs with the natural ligand are not available in PDB [23], we compared melatonin with the agomelatine in complex with *h*MT1 docking poses in 6ME5 [10] and 2-phenilmelatonin in complex with *h*MT2 in 6ME6 [19].

The identified docked ligand-protein complexes were further repositioned in orthosteric sites of *h*MT1 and *h*MT2 using a focused docking approach to generate the final complex, that has then minimized prior to proceeding to the subsequent molecular dynamics simulations. All six molecular complexes were then oriented in a lipid bilayer as *h*MTs using the OPM server database [55].

3.3. Molecular Dynamics Simulation of the *h*MTs-Ligands Complexes in Membrane

Molecular dynamics (MD) simulations in a membrane at physiological conditions were carried out for the *h*MTs-ligand complexes using GROMACS 2020.6 (<https://manual.gromacs.org/>) [62] in order to allow the receptor and its ligand fitting (Figure 13). The MD workflow provides three main steps: system preparation, simulation, and trajectory analysis. Melatonin and agomelatine charges were calculated with AM1/BCC method [30]. Ligands' parameters were retrieved with parmchk2 after the conversion of GAFF (General AMBER Force Field) [31] to AMBER ff14 atom types via the AMBER LEaP program, using AMBERff14SB [63] force field Topology; the ligands structural files were then converted from AMBER to GROMACS input files [58,59]. The assembled molecular systems (*h*MTs alone and in complex with ligands in the membrane) were retrieved by the CHARMM-GUI membrane builder (www.charmm-gui.org) [64–66]. All the *h*MTs were put into a lipid bilayer composed of phosphatidylcholine (POPC) and cholesterol (CHL1) using the spatial distribution of the OPM database [55,67].




Figure 13. Computational Workflow.

Water and ions were added to reach the physiological concentration of 0.15 M, using sodium (Na^+) and chloride (Cl^-) to neutralize the charge of the macromolecular system and TIP3P model for the solvent. AMBERff14SB force field [68] was used for energy calculation within Periodic Boundary Conditions (PBC) to decrease edge effects of tangential boxes in which the analyzed system is set; box size and total atomic number are reported in Supplementary Materials (Table S2).

Van der Waals forces calculations were carried out with a double cut-off value: 10–12 Å. Particle-Mesh-Ewald method allowed calculation of long-range electrostatic forces [69]. LINear Constraint Solver (LINCS) algorithm for hydrogen atoms was used with 2 fs as the time step [70]. All molecular systems underwent a complete minimization protocol prior to proceeding with MD simulations [71]. The equilibration was achieved starting from an initial canonical ensemble (NVT) equilibration step using temperature control of 310 K with a Berendsen thermostat [72] followed by three other following equilibration steps in an isobaric-isothermal ensemble (NPT). In the NPT ensemble, we maintained semi-isotropic conditions, keeping a constant 1 atm pressure. At the end of the process, a molecular dynamics simulation of 100 ns on each system was run. The temperature and the pressure of this process were controlled with a Nosé–Hoover thermostat [73,74] and a Parrinello–Rahman barostat [75].

The molecular mechanical Poisson-Boltzmann surface area (MMPBSA) calculation was carried out to estimate the free Gibbs binding energy of the simulated complexes [52]. MMPBSA methods are the most commonly used approaches to estimate the protein–ligand binding affinities. This calculation method provides an average of the free binding energy measured for a conformational ensemble of ligand–protein complex conformations [76,77].

3.4. In Vivo IOP Reduction Effects of Melatonin and Agomelatine

Animals were used in agreement with the Association for Research in Vision and Ophthalmology statement for the Use of Animals in Ophthalmic and Vision Research. The study also agrees with the European Communities Council Directive (2010/63/UE) and the Italian guidelines for animal care (DL 26/14). The experimental protocol was approved by the Commission for Animal Wellbeing of the University of Pisa (protocol n. 133/2019-PR). Rats (Sprague Dawley strain, 200 g body weight, 2–3 months of age) were obtained from Charles River Laboratories Italy (Calco, Italy). Before handling for tonometry, rats were acclimatized for 1 week. To evaluate the effects of melatonin (given at 0.5% or 0.2%), 0.2%

agomelatine and commercially available drugs commonly used to reduce IOP in glaucoma patients (i.e., 0.5% timolol and 0.2% brimonidine) on normotensive rats, 3 rats (6 eyes, 3 measurements/eye/time point) were used for each formulation. Rats were treated with 10 μ L per eye of formulations of melatonin prepared in Soluplus 1 mM (Merck) and borate buffer, pH 7.4. Ten μ L per eye of hypotensive drugs were administered as well. The IOP was measured from time 0 (before administration) to 6 h after administration using the TonoLab device (Icare, Finland).

For the hypertensive model, 3 rats (6 eyes, 3 measurements/eye/time point) were used for each formulation. Ocular hypertension was obtained through the injection in the anterior chamber of the rat eye of 15 μ L of 2% methylcellulose (MCE), as previously described [78]. Twenty-four hours after the MCE injection, the rats were utilized to evaluate the effects of 0.5% melatonin or other hypotensive drugs (0.5% timolol and 0.2% brimonidine).

3.5. *In Silico* Screening for Melatonin Agonists

In silico screening towards hMT1 and hMT2 receptors was carried out using as molecular libraries all the known 5-HT_{2C} antagonists and inverse agonists that were retrieved from the IUPHAR database (<https://www.guidetopharmacology.org/>) and Drug Bank repository (<https://go.drugbank.com/>). All molecular docking experiments were performed by AutoDock Vina version 1.1.2 [79,80]. The virtual screening software VINA was used to screen the collections of chosen drugs concerning the grid potential spread all over the protein surface. The resulting docked poses were clustered according to the protein regions in which the ligands bind. Finally, the resulting clusters were ranked based on the predicted binding energy and their population. Only clusters, including more than 10 compounds, were considered. Finally, the best scored compounds (top 100) were further selected based on their binding pose (compared with melatonin/agomelatine) in the orthosteric site and their specific interactions with cleft residues.

4. Conclusions

Glaucoma is one of the most important ocular neuropathies, often associated with an increased IOP. In this study, we aimed to open the way for the rational design of new compounds with high melatonergic activity and low toxicity by investigating the molecular basis of MTs agonists' activity. As a result, the computational findings defined the structural basis for agonistic activity and selectivity toward human melatonin receptors MT1 and MT2 of agomelatine and melatonin.

Specifically, the binding poses of melatonin and its agonist agomelatine within the orthosteric sites of hMTs were studied by molecular dynamics/molecular docking protocols. We predicted the binding poses of the natural ligand and the agomelatine positioning both in hMT1 and hMT2 in the membrane. Moreover, the binding stability was studied in terms of free Gibbs binding energy. The intermolecular interaction patterns were defined for each ligand and the involved melatonergic receptors, considering also the dynamical evolution in the biological environment (i.e., membrane). The results indicate that both ligands interact with the same key residues. MMPBSA calculation predicts that the two ligands have almost the same affinity towards the two hMTs receptors, as confirmed by experimental results. However, agomelatine shows a higher affinity for hMT2 than melatonin.

Besides, *in vivo* findings showed that agomelatine achieves a longer-lasting effect in downregulating IOP. This result could be explained by considering its additional known effect as an antagonist of the 5-HT_{2c} serotonin receptor, which is also involved in the IOP regulation pathway [53]. Hence, this peculiar behavior can open new frontiers in finding novel melatonergic agonists with more durable long-term effects.

In fact, libraries of 5-HT_{2c} antagonists have been collected and screened computationally regarding MT1 and MT2 to identify novel agonists. Among them, three compounds were selected based on their positioning inside the orthosteric site, binding pattern, and affinity, which were compared with melatonin and its agonist agomelatine. At present, in

our laboratory, in silico and in vitro testing studies are ongoing, aiming to identify safe compounds ready to use in clinical practice within a drug repurposing strategy.

Supplementary Materials: The supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/ijms24032863/s1>.

Author Contributions: Conceptualization, R.G. and M.C. (Mattia Cantarini); computational methodology, R.G. and M.C. (Mattia Cantarini); in vivo testing, M.D.M., R.A., A.C. and M.C. (Maurizio Cammalleri); software, E.L. and M.C. (Mattia Cantarini); validation, R.G., M.C. (Mattia Cantarini), and G.M.; formal analysis, M.C. (Mattia Cantarini) and D.R.; investigation, M.C. (Mattia Cantarini) M.C. (Maurizio Cammalleri), and R.A.; resources, R.G. and G.M.; data curation, M.C. (Mattia Cantarini), C.M., M.D.M. and R.A.; writing original draft preparation, M.C. (Mattia Cantarini) and R.G.; writing—review and editing, A.C., D.R., R.G., G.G., E.L. and M.D.M.; visualization, E.L. and G.G.; supervision, R.G.; project administration, R.G.; funding acquisition, R.G. and D.R. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was conducted in agreement with the Association for Research in Vision and Ophthalmology statement for the Use of Animals in Ophthalmic and Vision Research. The study also agrees with the European Communities Council Directive (2010/63/UE) and the Italian guidelines for animal care (DL 26/14). The experimental protocol was approved by the Commission for Animal Wellbeing of the University of Pisa (protocol n. 133/2019-PR).

Informed Consent Statement: Not applicable.

Data Availability Statement: Data are also reported in the Supplementary Material.

Acknowledgments: We would like to thank Fidia Pharmaceuticals for the generous contribution to the funding of the Mattia Cantarini's Ph.D. studentship within a Region Marche Eureka project.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Weinreb, R.N.; Aung, T.; Medeiros, F.A. The pathophysiology and treatment of glaucoma: A review. *JAMA J. Am. Med. Assoc.* **2014**, *311*, 1901–1911. [[CrossRef](#)]
2. Martínez-Águila, A.; Martín-Gil, A.; Carpena-Torres, C.; Pastrana, C.; Carracedo, G. Influence of circadian rhythm in the eye: Significance of melatonin in glaucoma. *Biomolecules* **2021**, *11*, 340. [[CrossRef](#)] [[PubMed](#)]
3. Agorastos, A.; Skevas, C.; Matthaiei, M.; Otte, C.; Klemm, M.; Richard, G.; Huber, C.G. Depression, anxiety, and disturbed sleep in glaucoma. *J. Neuropsychiatry Clin. Neurosci.* **2013**, *25*, 205–213. [[CrossRef](#)] [[PubMed](#)]
4. Hardeland, R.; Madrid, J.A.; Tan, D.-X.; Reiter, R.J. Melatonin, the circadian multioscillator system and health: The need for detailed analyses of peripheral melatonin signaling. *J. Pineal Res.* **2012**, *52*, 139–166. [[CrossRef](#)] [[PubMed](#)]
5. Agorastos, A.; Huber, C.G. The role of melatonin in glaucoma: Implications concerning pathophysiological relevance and therapeutic potential. *J. Pineal Res.* **2011**, *50*, 1–7. [[CrossRef](#)]
6. Jean-Louis, G.; Zizi, F.; Lazzaro, D.R.; Wolintz, A.H. Circadian rhythm dysfunction in glaucoma: A hypothesis. *J. Circadian Rhythm.* **2008**, *6*, 1. [[CrossRef](#)]
7. Alkozi, H.A.; Navarro, G.; Franco, R.; Pintor, J. Melatonin and the control of intraocular pressure. *Prog. Retin. Eye Res.* **2020**, *75*, 100798. [[CrossRef](#)]
8. Prnil, T.; Moongngarm, A.; Loypimai, P. Influence of pH, temperature, and light on the stability of melatonin in aqueous solutions and fruit juices. *Heliyon* **2020**, *6*, e03648. [[CrossRef](#)]
9. Audinot, V.; Mailliet, F.; Lahaye-Brasseur, C.; Bonnaud, A.; Le Gall, A.; Amossé, C.; Dromaint, S.; Rodriguez, M.; Nagel, N.; Galizzi, J.-P.; et al. New selective ligands of human cloned melatonin MT1 and MT2 receptors. *Naunyn Schmiedebergs Arch. Pharmacol.* **2003**, *367*, 553–561. [[CrossRef](#)]
10. Stauch, B.; Johansson, L.C.; McCorvy, J.D.; Patel, N.; Han, G.W.; Huang, X.-P.; Gati, C.; Batyuk, A.; Slocum, S.T.; Ishchenko, A.; et al. Structural basis of ligand recognition at the human MT1 melatonin receptor. *Nature* **2019**, *569*, 284–288. [[CrossRef](#)]
11. Manikandan, S. Agomelatine: A novel melatonergic antidepressant. *J. Pharmacol. Pharmacother.* **2010**, *1*, 122. [[CrossRef](#)] [[PubMed](#)]
12. Attwood, T.K.; Findlay, J.B.C. Fingerprinting g-protein-coupled receptors. *Protein Eng. Des. Sel.* **1994**, *7*, 195–203. [[CrossRef](#)]
13. Kolakowski, L.F. GCRDb: A G-protein-coupled receptor database. *Recept. Channels* **1994**, *2*, 1–7.
14. Schiöth, H.B.; Fredriksson, R. The GRAFS classification system of G-protein coupled receptors in comparative perspective. *Gen. Comp. Endocrinol.* **2005**, *142*, 94–101. [[CrossRef](#)] [[PubMed](#)]
15. Fredriksson, R.; Lagerström, M.C.; Lundin, L.G.; Schiöth, H.B. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. *Mol. Pharmacol.* **2003**, *63*, 1256–1272. [[CrossRef](#)]

16. Hu, G.-M.; Mai, T.-L.; Chen, C.-M. Visualizing the GPCR Network: Classification and Evolution. *Sci. Rep.* **2017**, *7*, 15495. [[CrossRef](#)] [[PubMed](#)]
17. Rasmussen, S.G.F.; DeVree, B.T.; Zou, Y.; Kruse, A.C.; Chung, K.Y.; Kobilka, T.S.; Thian, F.S.; Chae, P.S.; Pardon, E.; Calinski, D.; et al. Crystal structure of the β 2 adrenergic receptor-Gs protein complex. *Nature* **2011**, *477*, 549–557. [[CrossRef](#)]
18. Cherezov, V.; Rosenbaum, D.M.; Hanson, M.A.; Rasmussen, S.G.F.; Thian, F.S.; Kobilka, T.S.; Choi, H.-J.; Kuhn, P.; Weis, W.I.; Kobilka, B.K.; et al. High-resolution crystal structure of an engineered human β 2-adrenergic G protein-coupled receptor. *Science* **2007**, *318*, 1258–1265. [[CrossRef](#)]
19. Johansson, L.C.; Stauch, B.; McCorvy, J.D.; Han, G.W.; Patel, N.; Huang, X.-P.; Batyuk, A.; Gati, C.; Slocum, S.T.; Li, C.; et al. XFEL structures of the human MT2 melatonin receptor reveal the basis of subtype selectivity. *Nature* **2019**, *569*, 289–292. [[CrossRef](#)]
20. Warne, T.; Edwards, P.C.; Doré, A.S.; Leslie, A.G.W.; Tate, C.G. Molecular basis for high-affinity agonist binding in GPCRs. *Science* **2019**, *364*, 775–778. [[CrossRef](#)]
21. Patel, N.; Huang, X.P.; Grandner, J.M.; Johansson, L.C.; Stauch, B.; McCorvy, J.D.; Liu, Y.; Roth, B.; Katritch, V.; Department of Biological Sciences; et al. Structure-based discovery of potent and selective melatonin receptor agonists. *Elife* **2020**, *9*, e53779. [[CrossRef](#)] [[PubMed](#)]
22. Ballesteros, J.A.; Weinstein, H. Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. *Methods Neurosci.* **1995**, *25*, 366–428. [[CrossRef](#)]
23. Berman, H.M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T.N.; Weissig, H.; Shindyalov, I.N.; Bourne, P.E. The Protein Data Bank. *Nucleic Acids Res.* **2000**, *28*, 235–242. [[CrossRef](#)] [[PubMed](#)]
24. Isberg, V.; de Graaf, C.; Bortolato, A.; Cherezov, V.; Katritch, V.; Marshall, F.H.; Mordalski, S.; Pin, J.-P.; Stevens, R.C.; Vriend, G.; et al. Generic GPCR residue numbers—Aligning topology maps while minding the gaps. *Trends Pharmacol. Sci.* **2015**, *36*, 22–31. [[CrossRef](#)] [[PubMed](#)]
25. Ishchenko, A.; Stauch, B.; Han, G.W.; Batyuk, A.; Shiriaeva, A.; Li, C.; Zatsepin, N.; Weierstall, U.; Liu, W.; Nango, E.; et al. Toward G protein-coupled receptor structure-based drug design using X-ray lasers. *IUCr* **2019**, *6*, 1106–1119. [[CrossRef](#)]
26. Tian, W.; Chen, C.; Lei, X.; Zhao, J.; Liang, J. CASTp 3.0: Computed atlas of surface topography of proteins. *Nucleic Acids Res.* **2018**, *46*, W363–W367. [[CrossRef](#)]
27. Edelsbrunner, H.; Mücke, E.P. Three-Dimensional Alpha Shapes. *ACM Trans. Graph.* **1994**, *13*, 43–72. [[CrossRef](#)]
28. Ebalunode, J.O.; Ouyang, Z.; Liang, J.; Zheng, W. Novel approach to structure-based pharmacophore search using computational geometry and shape matching techniques. *J. Chem. Inf. Model.* **2008**, *48*, 889–901. [[CrossRef](#)]
29. Tian, W.; Liang, J. On quantification of geometry and topology of protein pockets and channels for assessing mutation effects. In Proceedings of the 2018 IEEE EMBS International Conference on Biomedical and Health Informatics, BHI 2018, Las Vegas, NV, USA, 4–7 March 2018; Volume 2018, pp. 263–266. [[CrossRef](#)]
30. Liang, J.; Woodward, C.; Edelsbrunner, H. Anatomy of protein pockets and cavities: Measurement of binding site geometry and implications for ligand design. *Protein Sci.* **1998**, *7*, 1884–1897. [[CrossRef](#)]
31. Edelsbrunner, H.; Facello, M.; Liang, J. On the definition and the construction of pockets in macromolecules. *Pac. Symp. Biocomput.* **1996**, *88*, 272–287. [[CrossRef](#)]
32. Pettersen, E.F.; Goddard, T.D.; Huang, C.C.; Couch, G.S.; Greenblatt, D.M.; Meng, E.C.; Ferrin, T.E. UCSF Chimera—A visualization system for exploratory research and analysis. *J. Comput. Chem.* **2004**, *25*, 1605–1612. [[CrossRef](#)] [[PubMed](#)]
33. Salentin, S.; Schreiber, S.; Haupt, V.J.; Adams, M.F.; Schroeder, M. PLIP: Fully automated protein-ligand interaction profiler. *Nucleic Acids Res.* **2015**, *43*, W443–W447. [[CrossRef](#)] [[PubMed](#)]
34. Trzaskowski, B.; Latek, D.; Yuan, S.; Ghoshdastider, U.; Debinski, A.; Filipek, S. Action of Molecular Switches in GPCRs—Theoretical and Experimental Studies. *Curr. Med. Chem.* **2012**, *19*, 1090–1109. [[CrossRef](#)] [[PubMed](#)]
35. Eddy, M.T.; Lee, M.-Y.; Gao, Z.-G.; White, K.L.; Didenko, T.; Horst, R.; Audet, M.; Stanczak, P.; McClary, K.M.; Han, G.W.; et al. Allosteric Coupling of Drug Binding and Intracellular Signaling in the A2A Adenosine Receptor. *Cell* **2018**, *172*, 68–80. [[CrossRef](#)]
36. Filipek, S. Molecular switches in GPCRs. *Curr. Opin. Struct. Biol.* **2019**, *55*, 114–120. [[CrossRef](#)] [[PubMed](#)]
37. Holst, B.; Nygaard, R.; Valentin-Hansen, L.; Bach, A.; Engelstoft, M.S.; Petersen, P.S.; Frimurer, T.M.; Schwartz, T.W. A conserved aromatic lock for the tryptophan rotameric switch in TM-VI of seven-transmembrane receptors. *J. Biol. Chem.* **2010**, *285*, 3973–3985. [[CrossRef](#)] [[PubMed](#)]
38. Wescott, M.P.; Kufareva, I.; Paes, C.; Goodman, J.R.; Thaker, Y.; Puffer, B.A.; Berdough, E.; Rucker, J.B.; Handel, T.M.; Doranz, B.J. Signal transmission through the CXC chemokine receptor 4 (CXCR4) transmembrane helices. *Proc. Natl. Acad. Sci. USA* **2016**, *113*, 9928–9933. [[CrossRef](#)]
39. Tehan, B.G.; Bortolato, A.; Blaney, F.E.; Weir, M.P.; Mason, J.S. Unifying Family A GPCR Theories of Activation. *Pharmacol. Ther.* **2014**, *143*, 51–60. [[CrossRef](#)]
40. Hofmann, K.P.; Scheerer, P.; Hildebrand, P.W.; Choe, H.-W.; Park, J.H.; Heck, M.; Ernst, O.P. A G protein-coupled receptor at work: The rhodopsin model. *Trends Biochem. Sci.* **2009**, *34*, 540–552. [[CrossRef](#)]
41. Nygaard, R.; Frimurer, T.M.; Holst, B.; Rosenkilde, M.M.; Schwartz, T.W. Ligand binding and micro-switches in 7TM receptor structures. *Trends Pharmacol. Sci.* **2009**, *30*, 249–259. [[CrossRef](#)]
42. Zhou, Q.; Yang, D.; Wu, M.; Guo, Y.; Guo, W.; Zhong, L.; Cai, X.; Dai, A.; Jang, W.; Shakhnovich, E.I.; et al. Common activation mechanism of class a GPCRs. *eLife* **2019**, *8*, e50279. [[CrossRef](#)] [[PubMed](#)]

43. Pala, D.; Lodola, A.; Bedini, A.; Spadoni, G.; Rivara, S. Homology models of melatonin receptors: Challenges and recent advances. *Int. J. Mol. Sci.* **2013**, *14*, 8093–8121. [[CrossRef](#)] [[PubMed](#)]
44. Frisch, M.J.; Trucks, G.W.; Schlegel, H.B.; Scuseria, G.E.; Robb, M.A.; Cheeseman, J.R.; Scalmani, G.; Barone, V.; Petersson, G.A.; Nakatsuji, H.; et al. *Gaussian 16, Revision C.01*; Gaussian Inc.: Wallingford, CT, USA, 2016.
45. Legros, C.; Brasseur, C.; Delagrangé, P.; Ducrot, P.; Nosjean, O.; Boutin, J.A. Alternative radioligands for investigating the molecular pharmacology of melatonin receptors. *J. Pharmacol. Exp. Ther.* **2016**, *356*, 681–692. [[CrossRef](#)] [[PubMed](#)]
46. Legros, C.; Matthey, U.; Grelak, T.; Pedragona-Moreau, S.; Hassler, W.; Yous, S.; Thomas, E.; Suzenet, F.; Folleas, B.; Lefoulon, F.; et al. New radioligands for describing the molecular pharmacology of MT1 and MT2 melatonin receptors. *Int. J. Mol. Sci.* **2013**, *14*, 8948–8962. [[CrossRef](#)] [[PubMed](#)]
47. Lavedan, C.; Forsberg, M.; Gentile, A.J. Tasimelteon: A selective and unique receptor binding profile. *Neuropharmacology* **2015**, *91*, 142–147. [[CrossRef](#)]
48. Sargsyan, K.; Grauffel, C.; Lim, C. How Molecular Size Impacts RMSD Applications in Molecular Dynamics Simulations. *J. Chem. Theory Comput.* **2017**, *13*, 1518–1524. [[CrossRef](#)]
49. Beresford, I.J.; Browning, C.; Starkey, S.J.; Brown, J.; Foord, S.M.; Coughlan, J.; North, P.C.; Dubocovich, M.L.; Hagan, R.M. GR196429: A nonindolic agonist at high-affinity melatonin receptors. *J. Pharmacol. Exp. Ther.* **1998**, *285*, 1239–1245.
50. Dubocovich, M.L. Characterization of a retinal melatonin receptor. *J. Pharmacol. Exp. Ther.* **1985**, *234*, 395–401. [[PubMed](#)]
51. Dubocovich, M.L.; Masana, M.I.; Iacob, S.; Sauri, D.M. Melatonin receptor antagonists that differentiate between the human Mel(1a) and Mel(1b) recombinant subtypes are used to assess the pharmacological profile of the rabbit retina ML(1) presynaptic heteroreceptor. *Naunyn Schmiedeberg's Arch. Pharmacol.* **1997**, *355*, 365–375. [[CrossRef](#)]
52. Wang, C.; Nguyen, P.H.; Pham, K.; Huynh, D.; Le, T.-B.N.; Wang, H.; Ren, P.; Luo, R. Calculating protein-ligand binding affinities with MMPBSA: Method and error analysis. *J. Comput. Chem.* **2016**, *37*, 2436–2446. [[CrossRef](#)]
53. Sharif, N.A. Ocular Hypotension: Involvement of Serotonergic 5-HT₂ Receptors. In *5-HT_{2C} Receptors in the Pathophysiology of CNS Disease*; Di Giovanni, G., Esposito, E., Di Matteo, V., Eds.; The Receptors; Humana Press: Totowa, NJ, USA, 2011; Volume 22. [[CrossRef](#)]
54. UniProt. UniProt: A worldwide hub of protein knowledge. *Nucleic Acids Res.* **2021**, *47*, D506–D515.
55. Lomize, M.A.; Pogozheva, I.D.; Joo, H.; Mosberg, H.I.; Lomize, A.L. OPM database and PPM web server: Resources for positioning of proteins in membranes. *Nucleic Acids Res.* **2012**, *40*, D370–D376. [[CrossRef](#)]
56. Lomize, A.L.; Pogozheva, I.D.; Lomize, M.A.; Mosberg, H.I. Positioning of proteins in membranes: A computational approach. *Protein Sci.* **2006**, *15*, 1318–1333. [[CrossRef](#)] [[PubMed](#)]
57. Biovia. *Dassault Systemes BIOVIA, Discovery Studio Modelling Environment, Release 4.5*; Accelrys Softw Inc.: San Diego, CA, USA, 2015.
58. Zisapel, N. New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation. *Br. J. Pharmacol.* **2018**, *175*, 3190–3199. [[CrossRef](#)]
59. Gioia, D.; Bertazzo, M.; Recanatini, M.; Masetti, M.; Cavalli, A. Dynamic docking: A paradigm shift in computational drug discovery. *Molecules* **2017**, *22*, 2029. [[CrossRef](#)]
60. Salmaso, V.; Moro, S. Bridging molecular docking to molecular dynamics in exploring ligand-protein recognition process: An overview. *Front. Pharmacol.* **2018**, *9*, 923. [[CrossRef](#)]
61. Morris, G.M.; Huey, R.; Lindstrom, W.; Sanner, M.F.; Belew, R.K.; Goodsell, D.S.; Olson, A.J. Software news and updates AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. *J. Comput. Chem.* **2009**, *30*, 2785–2791. [[CrossRef](#)]
62. Serrano Cardona, L.; Muñoz Mata, E. Paraninfo Digital. *Early Hum. Dev.* **2013**, *83*, 1–11. [[CrossRef](#)]
63. Massaccesi, L.; Laudadio, E.; Mobbili, G.; Minnelli, C.; Galeazzi, R. Cholesterol-mediated oligomerization pathways of serotonin G-coupled receptor 5-HT_{2C}. *Int. J. Biol. Macromol.* **2020**, *160*, 1090–1100. [[CrossRef](#)]
64. Abraham, M.J.; Murtola, T.; Schulz, R.; Páll, S.; Smith, J.C.; Hess, B.; Lindahl, E. Gromacs: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. *SoftwareX* **2015**, *1–2*, 19–25. [[CrossRef](#)]
65. Jo, S.; Kim, T.; Iyer, V.G.; Im, W. CHARMM-GUI: A web-based graphical user interface for CHARMM. *J. Comput. Chem.* **2008**, *29*, 1859–1865. [[CrossRef](#)]
66. Wu, E.L.; Cheng, X.; Jo, S.; Rui, H.; Song, K.C.; Dávila-Contreras, E.M.; Qi, Y.; Lee, J.; Monje-Galvan, V.; Venable, R.M.; et al. CHARMM-GUI membrane builder toward realistic biological membrane simulations. *J. Comput. Chem.* **2014**, *35*, 1997–2004. [[CrossRef](#)]
67. Jo, S.; Kim, T.; Im, W. Automated builder and database of protein/membrane complexes for molecular dynamics simulations. *PLoS ONE* **2007**, *2*, e880. [[CrossRef](#)]
68. Maier, J.A.; Martinez, C.; Kasavajhala, K.; Wickstrom, L.; Hauser, K.E.; Simmerling, C. ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB. *J. Chem. Theory Comput.* **2015**, *11*, 3696–3713. [[CrossRef](#)]
69. Darden, T.; York, D.; Pedersen, L. Particle mesh Ewald: An N·log(N) method for Ewald sums in large systems. *J. Chem. Phys.* **1993**, *98*, 10089–10092. [[CrossRef](#)]
70. Hess, B.; Bekker, H.; Berendsen, H.J.C.; Fraaije, J.G.E.M. LINCS: A Linear Constraint Solver for molecular simulations. *J. Comput. Chem.* **1997**, *18*, 1463–1472. [[CrossRef](#)]
71. Wardi, Y. A stochastic steepest-descent algorithm. *J. Optim. Theory Appl.* **1988**, *59*, 307–323. [[CrossRef](#)]

72. Berendsen, H.J.C.; Postma, J.P.M.; Van Gunsteren, W.F.; DiNola, A.; Haak, J.R. Molecular dynamics with coupling to an external bath. *J. Chem. Phys.* **1984**, *81*, 3684–3690. [[CrossRef](#)]
73. Nosé, S. A unified formulation of the constant temperature molecular dynamics methods. *J. Chem. Phys.* **1984**, *81*, 511–519. [[CrossRef](#)]
74. Hoover, W.G. Canonical dynamics: Equilibrium phase-space distributions. *Phys. Rev. A* **1985**, *31*, 1695–1697. [[CrossRef](#)] [[PubMed](#)]
75. Parrinello, M.; Rahman, A. Polymorphic transitions in single crystals: A new molecular dynamics 73.method. *J. Appl. Phys.* **1981**, *52*, 7182–7190. [[CrossRef](#)]
76. Wang, C.; Greene, D.; Xiao, L.; Qi, R.; Luo, R. Recent developments and applications of the MMPBSA method. *Front. Mol. Biosci.* **2018**, *4*, 87. [[CrossRef](#)] [[PubMed](#)]
77. Laudadio, E.; Mobbili, G.; Sorci, L.; Galeazzi, R.; Minnelli, C. Mechanistic insight toward EGFR activation induced by ATP: Role of mutations and water in ATP binding patterns. *J. Biomol. Struct. Dyn.* **2022**, 1–10. [[CrossRef](#)] [[PubMed](#)]
78. Monte, O.D.; Chu, C.C.J.; Fagan, N.A.; Chang, S.W.C. Specialized medial prefrontal-amygdala coordination in other-regarding decision preference. *Nat. Neurosci.* **2020**, *23*, 565–574. [[CrossRef](#)]
79. Eberhardt, J.; Santos-Martins, D.; Tillack, A.F.; Forli, S. AutoDock Vina 1.2.0: New Docking Methods, Expanded Force Field, and Python Bindings. *J. Chem. Inf. Model.* **2021**, *61*, 3891–3898. [[CrossRef](#)]
80. Trott, O.; Olson, A.J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *J. Comput. Chem.* **2010**, *31*, 455–461. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.